Hyriavenko N. I., Tsyndrenko N. L., Sumtsov D. G., Moskalenko R. A.
ANALYSIS OF ENDOMETRIAL CANCER INCIDENCE AMONG THE FEMALE POPULATION OF SUMY REGION IN THE PRE-WAR PERIOD AND UNDER MARTIAL LAW
Show/Download
About the author:
Hyriavenko N. I., Tsyndrenko N. L., Sumtsov D. G., Moskalenko R. A.
Heading:
CLINICAL AND EXPERIMENTAL MEDICINE
Type of article:
Scientific article
Annotation:
Endometrial cancer (EC) is one of the most common oncogynecological diseases in Ukraine. The Sumy region is a border region that, since February 2022, has been under the constant influence of security, demographic, and logistical factors that may affect the availability and timeliness of oncological diagnostics. The aim is to assess the dynamics of the incidence of EC among the female population of Sumy region in the pre-war (2017–2021) and war (2022–2024) periods, as well as to find out whether the martial law period was accompanied by an increase in the proportion of advanced (III–IV) stages. Retrospective population-based study based on open data from bulletins of the National Cancer Registry of Ukraine No. 19–26. The absolute number of first-time registered cases of EC, the incidence rate per 100,000 female population, the distribution by stage (I, II, III, IV, stage not established), and indicators of the quality of oncological care were analyzed. The comparison of relative values between groups was performed using the Pearson χ² test. When expected frequencies were small, Fisher’s exact test was used. Differences were considered statistically significant at p<0.05. The number of registered cases in 2017–2019 ranged from 216 to 253 per year. In 2020, there was a decrease to 178 cases (-28.2% compared to 2019), in 2022, to 144 cases (-28.4% compared to 2021 and -34.3% compared to the average pre-war level), with a subsequent recovery to 229 and 225 cases in 2023 and 2024. The proportion of patients with stages III–IV of EC during the study period tended to increase, reaching a maximum of 19.2% in 2022, compared with 8.7% in 2017. In subsequent years, this figure decreased to 11.4% in 2023 and 13.1% in 2024. At the same time, when comparing the pre-war and war periods, no statistically significant differences in the proportion of cases of stages III–IV were found (12.4% and 13.9%, respectively, p > 0.05). The highest level of one-year mortality was also observed among patients in whom the disease was diagnosed in 2022, and was 10.8%. The impact of martial law on the detection of EC in the Sumy region was in the nature of a sharp but short-term failure in 2022, with the maximum share of advanced stages for the entire period. In 2023–2024, the indicators returned to the pre-war level. The shift towards late stages began in 2020–2021, that is, it was laid by the COVID-19 pandemic.
Tags:
Bibliography:
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
- Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412-1428.
- Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110(4):354-361.
- Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
- Riera R, Bagattini AM, Pacheco RL, Pachito DV, Roitberg F, Ilbawi A. Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review. JCO Glob Oncol. 2021;7:311-323.
- Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087.
- Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023-1034.
- Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch FR, et al. The armed conflict and the impact on patients with cancer in Ukraine: urgent considerations. JCO Glob Oncol. 2022;8:e2200123.
- Talbot A, Connor SG, Austin K, Hannon T, Gabbay E, Clay TD. The impact of the 2022 Ukraine/Russian conflict on cancer clinical trials. J Int Med Res. 2022;50(12):3000605221143284.
- World Health Organization Regional Office for Europe. Ukraine crisis: public health situation analysis. Copenhagen: WHO Regional Office for Europe; 2022.
- National Cancer Registry of Ukraine. Cancer in Ukraine, 2017–2018. Bulletin of the National Cancer Registry of Ukraine No. 20. Kyiv: National Cancer Institute; 2019.
- National Cancer Registry of Ukraine. Cancer in Ukraine, 2020–2021. Bulletin of the National Cancer Registry of Ukraine No. 23. Kyiv: National Cancer Institute; 2022.
- National Cancer Registry of Ukraine. Cancer in Ukraine, 2022–2023. Bulletin of the National Cancer Registry of Ukraine No. 25. Kyiv: National Cancer Institute; 2024.
- National Cancer Registry of Ukraine. Cancer in Ukraine, 2023–2024. Bulletin of the National Cancer Registry of Ukraine No. 26. Kyiv: National Cancer Institute; 2025.
- State Statistics Service of Ukraine. Population of Ukraine as of January 1, 2022. Kyiv: State Statistics Service of Ukraine; 2022.
Publication of the article:
«Bulletin of problems biology and medicine», 2026 Issue 3, 182, 247-253 pages, index UDC 618.14-006.6-036.22(477.52)
